Biosion and ZhenGe Biotech Sign Global Strategic Partnership Agreement Accelerating Biosion’s Innovative Antibody Pipeline for IND Filing

NEWARK, Delaware, USA and NANJING, China, April 9,2020– Biosion Inc. and Shanghai ZhenGe Biotechnology Co. Ltd. jointly announced today that the two parties have signed a global strategic partnership agreement, to launch multiple projects with Biosion’s innovative antibody pipeline and ZhenGe’s CDMO (Contract Development and Manufacturing Organization) antibody technology platforms.

“We are very pleased to establish a strategic partnership with ZhenGeBiotech.” Said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion Inc., “ZhenGe’s advanced one-stop CDMO services will facilitate CMC development of our innovative biologic pipeline and accelerate our timeline for IND filings and clinical development.”

“We look forward to working with like-minded partners,” said Mr. Jianxin Chen, Founder, Chairman and CEO of ZhenGe Biotech. “Biosion’s innovative pipeline and ZhenGe’s industry leading CMC platform complement each other perfectly. I believe our cooperation will greatly promote the development of the next generation therapeutical biologics for patients in need.”

According to this agreement, the two parties will leverage the competitive advantages of Biosion’s innovative antibody discovery pipeline and ZhenGe’s advanced CDMO technology platforms. This partnership is expected to accelerate Biosion’s innovative antibody therapeutic pipelines and at the same time take advantage of ZhenGe’s development capability and manufacturing capacity. ZhenGe will provide Biosion with strong support in process development and production efficiency to accelerate Biosion’s new biologic clinical trial applications (IND) in China and globally. Details of the partnership terms were not disclosed.

About Biosion, Inc.

Biosion, Inc. is a global biotechnology company, focusing on the discovery and development of innovative therapeutics for oncology and immunological diseases. Leveraging its proprietary H³ (High-throughput, High-content, High-efficiency) antibody platform and SynAb™ technology, the company is committed to discovering and developing innovative biologics for patients with unmet medical needs. Biosion has established a proprietary therapeutic pipeline through its internal discovery efforts and collaborations with other biotech and pharmaceutical companies. For more information, please visit www.biosion.com

About ZhenGe Biotech

Shanghai ZhenGe Biotechnology Co., Ltd., is a nationwide recognized high-tech enterprise registered in the Shanghai Free Trade Zone. ZhenGe specializes in biologics CDMO services. It has an advanced Trinity platform which integrates cell line development, process development and cell culture medium development in synergy. ZhenGe’s capabilities include customized cell culture medium development and production, cell line construction and genetic engineering, and a one-stop service system for biopharmaceutical CMC (Chemistry, Manufacturing, and Control). ZhenGe has recently closed its Series A financing, raising over $51M. Please visit www.zgbiotech.com for more information. 

Biosion, Inc. Appoints Hugh Davis, Ph.D., Chief Operating Officer and President of Biosion USA, Inc.

NEWARKDelaware, and NANJING, China. March 23, 2020 – Biosion Inc., announced the appointment of Hugh M. Davis, Ph.D., as Chief Operating Officer, Biosion, Inc. and President of Biosion USA, Inc.  Dr. Davis joins Biosion from Frontage Laboratories, Inc., where he served as Chief Business Officer.

“We are pleased to welcome Hugh to the executive team and Board of Directors of Biosion. Hugh brings a tremendous wealth of industry experience in biologics research & development and across the biopharmaceutical value chain, including both strategy and execution,” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion, Inc. “Based on our proprietary H³ antibody discovery platform and SynAb™ technology, Biosion has built an innovative biotherapeutics portfolio to address key unmet medical needs of patients with immune and oncology-related diseases. Hugh will be integral to developing and driving portfolio and corporate strategy for the next stage of our growth. He will also oversee our global business operations and clinical development of our innovative therapeutics portfolio.”

Dr. Davis is a seasoned executive with over 30 years of experience in the development of biologics therapeutics. At Janssen R &D/Johnson & Johnson, Hugh was Vice President & Head, Biologics Development Sciences, Biophysics and Laboratory Operations. He and his team were instrumental in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvant®, Tremfya® and Darzalex®.  Following his tenure at Janssen R&D, Hugh joined Frontage Laboratories, Inc. as Chief Business Officer, where he played a critical role in leading the company to a very successful IPO in May of 2019. Dr. Davis holds a Ph.D. in Biochemistry from Villanova University, Villanova, PA, USA.

About Biosion, Inc.

Biosion, Inc. is a global biotechnology company, discovering and developing innovative therapeutics for oncology and immunological diseases. Leveraging our proprietary H³ (High-throughput, High-content, High-efficiency) antibody platform and SynAb™ technology, the company is committed to discovering and developing innovative biologics for patients with unmet medical needs. The company is building a proprietary therapeutic pipeline through its innovative internal discovery efforts and through co-development programs in collaboration with biotech and pharmaceutical companies. For more information, visit www.biosion.com

Contacts:
Shengmei Ma
Biosion USA, Inc.
Newark, DE
+1-508-410-6008
shengmei.ma@biosion.com

Ailie Su
Biosion, Inc.
Nanjing, China
+86-199-5241-5530
ailie.su@biosion.com

Biosynergics, Inc. Completes Series A Financing and Company Restructuring

On October 29, 2017, Biosynergics, Inc. (“Biosynergics”), a China-based startup biotech company, announced that it has completed a 30 million RMB Series A financing. The Series A round was exclusively invested in by Shenzhen Renhe Capital. After completion of the financing, Shenzhen Renhe Capital (“SRC”) and Biosynergics co-registered a new entity named as Biosion, Inc. (“Biosion”) in Nanjing, China. Going forward, Biosynergics will operate as a wholly-owned subsidiary of Biosion.

The rationale for restructuring of Biosynergics was driven by three considerations. First, Biosyngerics has developed and directed its core antibody drug discovery business to minimize preclinical drug development risks while accelerating the clinical and commercial antibody drug pipeline success of its current and future biopharmaceutical clients. Second, Biosynergics has successfully recruited highly trained scientific talent to continue its execution on its business plan and will continue putting the effort of attracting more top talents in the near future. Third, the critical investment and restructuring required to create Biosion, now enables a strategic path forward to enhance and expand its capabilities as necessary through a future IPO. The newly established company, Biosion will focus on innovative antibody drug discovery and early preclinical drug development while Biosynergics will continue its existing business scope of In VitroDiagnosis(IVD) critical raw materials supply and CRO services.

Dr. Mingjiu Chen, Founder and CEO of Biosion stated “We are very pleased that our recent achievements and future growth potential were recognized by the Renhe Capital team. Exploiting our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ (Synergistic Antibody) technology, we are able to interrogate very large, program-specific, antibody collections that result in the discovery and development of both First-in-Class and Best-in-Class antibody drug candidates. With SRC’s investment and their capital management experience, we anticipate that our antibody drug discovery pipeline will be accelerated and our corporate operation efficiency will be further optimized.”

“The demonstrated excellent performance of the Biosynergics team to date and the great growth potential of China’s biotechnology industry are the main considerations for today’s investment,” commented Mr. Weichun Ji, CEO of Shenzhen Renhe Capital. “Furthermore, leveraging their core business of innovative antibody drug discovery and early development, Biosion offers a very unique value proposition to its biopharmaceutical partners to increase the speed and success rate of their antibody drug development. Biosion team has demonstrated a combination of great technical expertise, a thoughtful and clear understanding of marketing strategy, and a strong implementation capability. During our due diligence, we have received very positive feedbacks from both Biosion’s current clients and from the experts from the industry. We are truly pleased to work with Biosion team to promote the innovation of China’s antibody drug industry.”

About Biosion, Inc.

Biosion is a China-based biotech company dedicated to the discovery and development of innovative antibody drugs. Based on our proprietary H³ antibody platform and SynAb™ technology, Biosion is committed to develop biological molecules with superior drug properties and/or novel mechanism of actions to known and novel drug targets. In the past years, Biosion team has successfully delivered multiple therapeutic antibody discovery projects to their clients, and established extensive business relations with the well-known biopharmaceutical companies in China. For more information, please visit www.biosion.com.

About Renhe Capital

Founded in 2012, Shenzhen Renhe Captial (SRC) is a professional asset management company. The company’s core management team investment experience has more than 19 years in the capital market with a wide range of network resources and customer resources, along with many fund management companies, securities companies, listed companies to maintain close relations of cooperation. On March 25, 2014, SRC was awarded the joint venture “private equity fund manager registration certificate” for the top 100 filing of the private management agencies by China Securities Investment Fund Association.

Close Bitnami banner
Bitnami